Levels of evidence and grades of recommendation supporting European society for medical oncology clinical practice guidelines.

Select Content Type
Clinical Guidelines
Authored By
Skelin M, Perkov-Stipičin B, Vušković S, Šandrk Plehaček M, Bašić A, Šarčević D, Ilić M, Krečak I
Authored On
Interests
Oncology
Speciality
Oncology
Book Detail
volume
32
ISSN
1555-3906
No. of pages
9
Publication Date
Actions
Download in App
Event Data
{"article_title":"Levels of evidence and grades of recommendation supporting European society for medical oncology clinical practice guidelines.","author":"\"Skelin, Marko , Perkov-Stipi\u010din, Bruna , Vu\u0161kovi\u0107, Sanja , \u0160andrk Pleha\u010dek, Marina , Ba\u0161i\u0107, Ane , \u0160ar\u010devi\u0107, David , Ili\u0107, Maja , Kre\u010dak, Ivan\"","journal_title":"Oncology research","issn":"1555-3906 ; Electronic","isbn":"","publication_date":"20240423","volume":"32","issue":"5","first_page":"807","page_count":"9","accession_number":"38686053","doi":"10.32604\/or.2024.048948","publisher":"Tech Science Press","doctype":"Journal Article; Practice Guideline","subjects":"Psychology ","interest_area":["Oncology"],"abstract":"The authors declare that they have no conflicts of interest to report regarding the present study.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=38686053&authtype=shib&custid=ns346513","isPdfLink":true,"isSAML":false,"additionalInfo":{"Authored_By":"Skelin M, Perkov-Stipi\u010din B, Vu\u0161kovi\u0107 S, \u0160andrk Pleha\u010dek M, Ba\u0161i\u0107 A, \u0160ar\u010devi\u0107 D, Ili\u0107 M, Kre\u010dak I","Journal_Info":"Publisher: Tech Science Press Country of Publication: United States NLM ID: 9208097 Publication Model: eCollection Cited Medium: Internet ISSN: 1555-3906 (Electronic) Linking ISSN: 09650407 NLM ISO Abbreviation: Oncol Res Subsets: MEDLINE","Publication_Type":"Journal Article","Published_Date":"2024-04-23","Source":"Oncology research [Oncol Res] 2024 Apr 23; Vol. 32 (5), pp. 807-815. Date of Electronic Publication: 2024 Apr 23 (Print Publication: 2024).","Languages":"English","Electronic_ISSN":"1555-3906","MeSH_Terms":"Practice Guidelines as Topic*\/standards , Medical Oncology*\/standards , Medical Oncology*\/methods , Neoplasms*\/therapy, Humans ; Europe ; Evidence-Based Medicine\/standards ; Evidence-Based Medicine\/methods ; Societies, Medical","Subjects":"Humans, Europe, Evidence-Based Medicine standards, Evidence-Based Medicine methods, Societies, Medical, Practice Guidelines as Topic standards, Medical Oncology standards, Medical Oncology methods, Neoplasms therapy","Title_Abbreviations":"Oncology research","Volume":"32"},"header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"38686053","RelevancyScore":"914","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"914.451110839844"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=38686053&authtype=shib&custid=ns346513&group=main&profile=eds","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=38686053&authtype=shib&custid=ns346513&group=main&profile=eds"}
ISSN
1555-3906 ; Electronic
IS_Ebsco
true
Upload Link
https://search.ebscohost.com/login.aspx?direct=true&db=mdl&AN=38686053&authtype=shib&custid=ns346513
Additional Info
["Skelin M, Perkov-Stipi\u010din B, Vu\u0161kovi\u0107 S, \u0160andrk Pleha\u010dek M, Ba\u0161i\u0107 A, \u0160ar\u010devi\u0107 D, Ili\u0107 M, Kre\u010dak I","Publisher: Tech Science Press Country of Publication: United States NLM ID: 9208097 Publication Model: eCollection Cited Medium: Internet ISSN: 1555-3906 (Electronic) Linking ISSN: 09650407 NLM ISO Abbreviation: Oncol Res Subsets: MEDLINE","Journal Article","2024-04-23","Oncology research [Oncol Res] 2024 Apr 23; Vol. 32 (5), pp. 807-815. Date of Electronic Publication: 2024 Apr 23 (Print Publication: 2024).","English","1555-3906","Practice Guidelines as Topic*\/standards , Medical Oncology*\/standards , Medical Oncology*\/methods , Neoplasms*\/therapy, Humans ; Europe ; Evidence-Based Medicine\/standards ; Evidence-Based Medicine\/methods ; Societies, Medical","Humans, Europe, Evidence-Based Medicine standards, Evidence-Based Medicine methods, Societies, Medical, Practice Guidelines as Topic standards, Medical Oncology standards, Medical Oncology methods, Neoplasms therapy","Oncology research","32"]
Description
Background: The European Society for Medical Oncology (ESMO) guidelines are among the most comprehensive and widely used clinical practice guidelines (CPGs) globally. However, the level of scientific evidence supporting ESMO CPG recommendations has not been systematically investigated. This study assessed ESMO CPG levels of evidence (LOE) and grades of recommendations (GOR), as well as their trends over time across various cancer settings.<br />Methods: We manually extracted every recommendation with the Infectious Diseases Society of America (IDSA) classification from each CPG. We examined the distribution of LOE and GOR in all available ESMO CPG guidelines across different topics and cancer types.<br />Results: Among the 1,823 recommendations in the current CPG, 30% were classified as LOE I, and 43% were classified as GOR A. Overall, there was a slight decrease in LOE I (-2%) and an increase in the proportion of GOR A (+1%) in the current CPG compared to previous versions. The proportion of GOR A recommendations based on higher levels of evidence such as randomized trials (LOE I-II) shows a decrease (71% vs . 63%, p = 0.009) while recommendations based on lower levels of evidence (LOE III-V) show an increase (29% vs . 37%, p = 0.01) between previous and current version. In the current versions, the highest proportion of LOE I (42%) was found in recommendations related to pharmacotherapy, while the highest proportion of GOR A recommendations was found in the areas of pathology (50%) and diagnostic (50%) recommendations. Significant variability in LOE I and GOR A recommendations and their changes over time was observed across different cancer types.<br />Conclusion: One-third of the current ESMO CPG recommendations are supported by the highest level of evidence. More well-designed randomized clinical trials are needed to increase the proportion of LOE I and GOR A recommendations, ultimately leading to improved outcomes for cancer patients.<br /> (© 2024 Skelin et al.)
Published Date